Saturday 17 October 2026
Export LPCN’s income statement to Excel — free account
Lipocine Inc.
LPCN Healthcare Biotechnology
Lipocine Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 million, down 82.3% from fiscal 2024. In the quarter to June 2026, revenue fell 69.5%, EPS grew 22.0% and free cash flow fell 60.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.56
0.12
−7.14%
Follow LPCN
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
— | 1 | 2 | 2 |
| (32.92%) | (54.28%) | (54.41%) | (60.94%) | ||
| (29.78%) | (48.73%) | (49.87%) | (55.89%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(38.78%) | (66.61%) | (50.14%) | (54.51%) | |
Average Days of Receivables |
9.74 | 214.12 | 42.07 | 67.72 | |
Free Cash Flow per Share |
(0.95) | (1.79) | (1.48) | (1.36) | |
Free Cash Flow |
(5.14) | (9.76) | (10.05) | (11.19) | |
| Other line items | |||||
Cash ROIC |
(17.56%) | (33.19%) | (21.13%) | (24.85%) | |
Accounts Receivable Turnover |
41.81 | 2.88 | 9.77 | 7.60 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
161.45% | 434.26% | 513.77% | 649.34% | |
Selling, General and Administrative Expense of Revenue |
84.53% | 190.42% | 192.09% | 251.46% | |
Share Based Compensation of Revenue |
6.68% | 12.27% | 11.83% | 14.64% | |
Operating CF/Net income |
0.94 | 1.01 | 0.88 | 0.94 | |
Depreciation/Fixed assets |
(1.54) | (1.27) | (1.91) | (2.71) | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.80 | 0.36 | 0.29 | 0.19 | |
Operating CF per Share |
(0.95) | (1.79) | (1.48) | (1.36) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates